and Sanofi/Regeneron’s Praluent (alirocumab) – which have been available for some years but still aren’t being widely used. Inclisiran is currently in phase 3 testing as an add-on to statin ...

The US regulator issued Novartis with a complete response letter (CRL) for inclisiran a year ago ... and Sanofi/Regeneron's Praluent (alirocumab) – but after a lead-in period is dosed only ...